Methods of preparing pharmaceutical solid state forms

A method to make crystalline anhydrate Form III 17α-ethynyl-5α-androstane-3α,17β-diol that is characterized by or has (i) an X-ray powder diffraction pattern with peak positions of 9.85, 11.33, 15.96, 16.48 and 18.95±0.10 degrees 2-theta or peak positions of 15.96, 16.48 and 18.95±0.10 degrees 2-theta and one two or three peak positions at 9.30, 11.33, 13.45, 16.16 or 17.42±0.10 degrees 2-theta, (ii) an IR-Raman spectroscopy spectrum with peak positions at 1236, 1190 and 490 cm−1, optionally with one, two or three peak positions at 1458, 1435, 619, 604, 526, 237 or 206 cm−1 or is represented by FIG. 5A or FIG. 5B, and/or (iii) a differential scanning calorimetry thermogram with a prominent endotherm at 164° C. obtained using a temperature ramp of 10° C./min and has a thermogravimetric analysis weight loss of 0.5% or less when heated between 40° C. to 105° C. using a temperature ramp of 10° C./min, said method comprising,

• sufficiently drying at ambient temperature (about 22-27° C.) under vacuum crystalline solvate Form I 17α-ethynyl-5α-androstane-3α,17β-diol,
• or sufficiently heating crystalline solvate Form I 17α-ethynyl-5α-androstane-3α,17β-diol at a temperature(s) from above ambient temperature to a maximum of about 75° C.,
• until the dried or heated material shows a loss on heating of less than 0.5% by weight when heated to 50° C.±5°.